Clinical Trial Update: A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safety and effects of ADH-1 given intravenously as a single agent in cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ADH-1

Snippet

Sponsor: Adherex Technologies, Inc. | Conditions: Neoplasms | Phase 2 | Status: COMPLETED